Clinical trials: Epirubicin
Triple Negative Breast Cancer
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
The study is being conducted to evaluate the efficacy, safety and tolerability of Camrelizumab Combination With Nab-Paclitaxel and Epirubicin as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04676997
- Testing
- Camrelizumab, Nab paclitaxel, Epirubicin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Cancer Hospital and Institute
Gastric Cancer
Observational Study of Perioperative Chemotherapy in Gastric Cancer
This study will assess the efficacy and toxicity of perioperative chemotherapy with Epirubicin + Cisplatin + Capecitabine (ECX) in routine clinical practice in a network of public hospitals in Santiago, Chile.
- Trial name
- PRECISO (NCT01633203)
- Testing
- epirubicin + cisplatin + capecitabine polychemotherapy
- Where
- Chile
- Volunteers
- 61 people
- Sponsor
- Grupo Oncologico Cooperativo Chileno de Investigation
Cancer-related Fatigue, Neutropenia, Malignant
PG2 Breast Cancer Evaluation in Adjuvant Medicine Study
Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence.
- Trial name
- PG2 BEAM (NCT03314805)
- Testing
- Astragalus polysaccharides 500 mg, EC Chemotherapy
- Where
- 5 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- PhytoHealth Corporation
Multiple Myeloma, Primary Plasma Cell Leukemia
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma
- Conditions
- Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
- Trial name
- NCT06140966
- Testing
- Daratumumab, Carfilzomib, Lenalidomide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
TNBC
A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer
Camrelizumab + Chemoradiotherapy for Early TNBC Sponsor/Leading Center: Tianjin Medical University Cancer Institute and Hospital Study Type: Single-arm, single-center, Phase Ⅱ clinical study Planned Enrollment: 43 patients…
- Trial name
- NCT07491822
- Testing
- treatment group
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic/Recurrent Breast Cancer
Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer
This is a Phase I, multi-centre, open-label, cross-over pharmacokinetic study designed to investigate whether the co-administration of a fixed dose of tesmilifene alters the plasma pharmacokinetics of a standard regimen of…
- Trial name
- NCT00364754
- Testing
- Tesmilifene (YMB 1002)
- Where
- 10 sites in Georgia, Russia and 1 more
- Volunteers
- 28 people
- Sponsor
- YM BioSciences
Bladder Cancer, Epirubicin Adverse Reaction
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
In this study, the local and systemic side effects, tumor recurrens and progression rates of single or continuous epirubicin instillation during the early postoperative period were investigated in low and intermediate risk…
- Conditions
- Bladder Cancer, Epirubicin Adverse Reaction, Superficial Bladder Cancer, Tumor Recurrence
- Trial name
- NCT05084586
- Testing
- Intravesical Solution
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Ankara Training and Research Hospital
Lymphoma, B-Cell
R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
In this study，lenalidomide was added in the first-line treatment in the newly diagnosed highly invasively non-Hodgkin B-cell lymphoma. The R2-CHOP/R2-EPOCH etc was applied compared with the classical R-CHOP/R-EPOCH etc.
- Trial name
- NCT04152577
- Testing
- R2-combination chemotherapy, R-combination chemotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong Provincial Hospital
Breast Cancer, HER2 Positive
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
- Trial name
- TRAIN-2 (NCT01996267)
- Testing
- PTC+Pertuzumab, FEC-T+Pertuzumab
- Where
- 33 sites in Netherlands
- Volunteers
- 437 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, fluorouracil, and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT01031030
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Volunteers
- 800 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Hepatocellular Carcinoma (HCC)
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical…
- Trial name
- NCT05213637
- Testing
- Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chinese PLA General Hospital
Metastatic Breast Cancer
Phase I Combination w/ Epirubicin
Tumor response information was obtained for all participants who received at least 2 cycles of study drug, underwent requisite baseline and on-treatment disease assessments and had at least one post-treatment assessment.
- Trial name
- NCT00322374
- Testing
- Ixabepilone, Epirubicin
- Where
- 2 sites in France, Italy
- Volunteers
- 42 people
- Sponsor
- R-Pharm
Diffuse Large B Cell Lymphoma
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy.
- Trial name
- NCT05290090
- Testing
- Rituximab, Lenalidomide, Zanubrutinib and RCHOP
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer, Gastric Cancer
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments.
- Trial name
- NCT00737438
- Testing
- epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002615
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Medical Research Council
Breast Cancer, Paclitaxel
Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer
RATIONALE: Adjuvant chemotherapy has been proven to reduce significantly the risk for relapse and death in women with operable breast cancer.In the North American Inter-Group factorial trial design (CALGB 9741) the concept of…
- Conditions
- Breast Cancer, Paclitaxel, Epirubicin, Cyclophosphamide
- Trial name
- PATEN (NCT01848197)
- Testing
- paclitaxel
- Volunteers
- 1,000 people
- Sponsor
- Taizhou Hospital
pCR Rate, BCT Rate
NeoMET Study in Neoadjuvant Treatment of Breast Cancer
To evaluate docetaxel, epirubicin and cyclophosphomide (TEC) with TEC plus metformin in neoadjuvant treatment of breast cancer patients.
- Conditions
- pCR Rate, BCT Rate, Safety
- Trial name
- NeoMET (NCT01929811)
- Testing
- Metformin, Docetaxel, Epirubicin
- Where
- 2 sites in China
- Volunteers
- 92 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hepatocellular Carcinoma
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Lenvatinib in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until the death or intolerable…
- Trial name
- NCT04490694
- Testing
- Lenvatinib, TACE
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Zhongshan Hospital
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the…
- Conditions
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma
- Trial name
- FAST (NCT01630083)
- Testing
- epirubicin, oxaliplatin, capecitabine
- Where
- 48 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 252 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Cancer
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Investigators propose to study the efficacy of Bevacizumab plus systemic chemotherapy prior to surgery in order to make a locally advanced tumor operable.
- Trial name
- NCT01985841
- Testing
- Bevacizumb, 5-Fluorouracil, Epirubicin
- Where
- 6 sites in Greece
- Volunteers
- 34 people
- Sponsor
- Hellenic Oncology Research Group